# SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma

> **NCT07749859** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 80 (estimated)

## Conditions studied

- Advanced Unresectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** Retlirafusp alfa Injection, apatinib

## Key facts

- **NCT ID:** NCT07749859
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2028-07
- **Final completion:** 2028-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07749859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07749859, "SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07749859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*